← SynDRA
CEP-32496
SynDRA canonical compound SYN0029192 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | BRAF |
|---|
| Mechanism of action | RAF inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- RAF inhibitor
- BRAF INHIBITOR
- Serine/threonine-protein kinase B-raf inhibitor
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- RET INHIBITOR
- Tyrosine-protein kinase receptor RET inhibitor
- RAF1 INHIBITOR
Cross-references
Synonyms
- Agerafenib
- RXDX-105
- AB-024
- AC-013773
- B-RAF kinase inhibitors (melanoma), Ambit/Cephalon
- CEP 32496
- Rxdx 105
- AC013773
- RefChem:110134
- MFCD22124524
- UNII-78I4VEX88N
- C24H22F3N5O5
- CEP32496
- AGERAFENIB [INN]
- AGERAFENIB [WHO-DD]
- CEP-32496 (free base)
- GTPL7880
- orb1306565
- SCHEMBL1015932
- RXDX 105 [WHO-DD]
- SCHEMBL29351427
- SCHEMBL29697285
- DKNUPRMJNUQNHR-UHFFFAOYSA-N
- GLXC-90328
- HMS3653J19
- EX-A1481
- BDBM50382959
- NSC776043
- NSC800070
- s8015
- AKOS023600525
- AKOS032949984
- CCG-269834
- CEP-32496?
- CS-1115
- NSC-776043
- NSC-800070
- SB20796
Look up CEP-32496 in the interactive SynDRA portal →